ResearcherKanazawa UniversityNo recent work listed
Yoshiharu Motoo
Matched on ORCID iD 0000-0002-0776-6434; OpenAlex author ID A5008116561. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 1, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 12
2011: 2 papers · 2012: 4 papers · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper
Papers 8
- [Long-Term Survival Due to Combination Therapy in a Patient with Locally Advanced Body-Tail Pancreatic Cancer]. Last author PMID 29394638↗
- Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. Co-author DOI 10.1371/journal.pone.0055289↗
- Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine. Last author DOI 10.1007/s00535-011-0484-9↗
- Multiple factors influencing the release of hTERT mRNA from pancreatic cancer cell lines in in vitro culture. Co-author DOI 10.1042/cbi20090471↗
- Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro. Co-author DOI 10.3892/or.2012.2020↗
- Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer. First author DOI 10.4103/1477-3163.100866↗
- Human SMG-1 is involved in gemcitabine-induced primary microRNA-155/BIC up-regulation in human pancreatic cancer PANC-1 cells. Last author DOI 10.1097/mpa.0b013e3181e89f74↗
- Metabolic disorder, inflammation, and deregulated molecular pathways converging in pancreatic cancer development: implications for new therapeutic strategies. Co-author DOI 10.3390/cancers3010446↗
Closest collaborators
The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Takeo Shimasaki · 6 shared papers, 2011–2013 · strength 0.19
- Paper Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer. DOI 10.4103/1477-3163.100866↗
- Paper Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro. DOI 10.3892/or.2012.2020↗
- Paper Metabolic disorder, inflammation, and deregulated molecular pathways converging in pancreatic cancer development: impli… DOI 10.3390/cancers3010446↗
- Toshinari Minamoto Md · 4 shared papers, 2011–2013 · strength 0.13
- Paper Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer. DOI 10.4103/1477-3163.100866↗
- Paper Metabolic disorder, inflammation, and deregulated molecular pathways converging in pancreatic cancer development: impli… DOI 10.3390/cancers3010446↗
- Paper Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. DOI 10.1371/journal.pone.0055289↗
- Ayako Kitano · 3 shared papers, 2012–2013 · strength 0.10
- Paper Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer. DOI 10.4103/1477-3163.100866↗
- Paper Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. DOI 10.1371/journal.pone.0055289↗
- Paper Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine. DOI 10.1007/s00535-011-0484-9↗
- Takeo Kosaka · 1 shared paper, 2017 · strength 0.06
- Nobuhiko Ueda · 1 shared paper, 2017 · strength 0.06
- Naohisa Tomosugi · 2 shared papers, 2012 · strength 0.06
- Takanobu Takata · 2 shared papers, 2012 · strength 0.06
- Gensaku Okada · 1 shared paper, 2012 · strength 0.03
- Koushiro Ohtsubo · 1 shared paper, 2012 · strength 0.03
- Norio Sawabu · 1 shared paper, 2012 · strength 0.03
- Yoshimichi Sai · 1 shared paper, 2013 · strength 0.03
- Qisheng Xia · 1 shared paper, 2011 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.